Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
A blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3) was tested for efficacy in a primate model. Aotus nancymai monkeys were vaccinated with yeast-expressed MSP3 before a lethal challenge with Plasmodium falciparum parasites. Five of 7 control monkeys had acute infections and required treatment to control parasitemia. Only 1 of 7 monkeys vaccinated with MSP3 required this treatment. The efficacy of the MSP3 vaccination appeared to be comparable to that of MSP1(42), a leading asexual vaccine candidate, in response to which 2 monkeys experienced acute infections. In the MSP3-vaccinated group, protection correlated with prechallenge titers of antibody to MSP3. In the MSP1 and control groups, protection correlated with antibody to MSP3 raised by challenge infection.
Hisaeda
Hajime
H
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases/NIH, Rockville, MD 20852, USA.
Saul
Allan
A
Reece
Joshua J
JJ
Kennedy
Michael C
MC
Long
Carole A
CA
Miller
Louis H
LH
Stowers
Anthony W
AW
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000942:Antigens, Bacterial; D016645:Aotidae; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016778:Malaria, Falciparum / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000276:immunology; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000378:metabolism; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000913:Antibodies, Protozoan; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D017780:Malaria Vaccines; D014614:Vaccines, Synthetic; C103346:major surface protein 3, Anaplasma marginale